| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Progressive liver injury and increased mortality risk in COVID-19 patients: A retrospective cohort study in China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shui-Sheng Zhang, Li Dong, Gao-Ming Wang, Yuan Tian, Xiao-Fang Ye, Yue Zhao, Zheng-Yin Liu, Jia-Yu Zhai, Zhi-Ling Zhao, Jun-Hong Wang, Hui-Min Zhang, Xiao-Long Li, Chang-Xin Wu, Cai-Ting Yang, Li-Juan Yang, Hai-Xia Du, Hui Wang, Qing-Gang Ge, Dian-Rong Xiu and Ning Shen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qing-Gang Ge, MD, PhD, Chief Doctor, Professor, Critical Medical Department, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing 100191, China. bjgeqinggang@126.com |
| Key Words |
COVID-19; Liver injury; Prognosis; Risk factors; Drugs; Alanine aminotransferase |
| Core Tip |
The prevalence of liver injury during hospitalisation in patients with coronavirus disease 2019 (COVID-19) is high and also can be fatal. Therefore, high-risk population, especially aged ≥ 65 years, or female, or with other comorbidities should be intensively monitored. On-admission total bilirubin has strongest correlation with the prognosis of COVID-19 patients, which can be used for monitoring of COVID-19 patients at risk of liver injury. Intravenous nutrition and antibiotics are associated with abnormal liver biochemistry; these drugs should be given with caution. Hepatoprotective drugs are favorable for patients with liver injury. |
| Publish Date |
2021-03-03 10:02 |
| Citation |
Zhang SS, Dong L, Wang GM, Tian Y, Ye XF, Zhao Y, Liu ZY, Zhai JY, Zhao ZL, Wang JH, Zhang HM, Li XL, Wu CX, Yang CT, Yang LJ, Du HX, Wang H, Ge QG, Xiu DR, Shen N. Progressive liver injury and increased mortality risk in COVID-19 patients: A retrospective cohort study in China. World J Gastroenterol 2021; 27(9): 835-853 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i9/835.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i9.835 |
